Fig. 6.

Transcriptomic profile and response to treatment. a: Kaplan–Meier curve for patients with locally advanced (left) or metastatic (right) pancreatic cancer who received a gemcitabine-based regimen as first-line treatment (L1), stratified by the transcriptome-based GemPred signature. b: Forest plot of the interaction between gemcitabine-based L1 and GemPred among all patients with advanced diseases (i.e., locally advanced plus metastatic). The Forest plot and Cox proportional hazards regression is stratified by disease stage and performance status.